ARTICLE | Company News
CAT, Elan neurological deal
January 25, 2001 8:00 AM UTC
Cambridge Antibody Technology (LSE:CAT) and ELN will discover and develop antibody-based therapeutics to treat neurological disorders. The companies will share 50/50 R&D costs and commercialization pr...